Aim. The aim of the study was to evaluate the clinical efficacy of immunocorrecting therapy in patients with atopic dermatitis (AtD) using a polypeptide drug with the anti-inflammatory and anti-allergic activity, derived from a thermophilic Staphylococcus aureus strain. Material and methods. 41 patients with AtD complicated by a secondary infection were examined. An immunological examination included determination of cellular and humoral immunity indicators and cytokines. Combined therapy included a polypeptide drug produced from a thermophilic S.aureus strain. Assessement of the clinical efficacy was performed using the SCORAD scale as well as by evaluation of cellular and humoral immunity indicators and cytokines before and after therapy. Results. On the background of immunocorrecting therapy, a decrease in the severity of AtD on the SCORAD scale during subsequent relapses amounted to 43.6%, and the serum IgE level decreased in 2.6 times. The immunomodulatory effect on indicators of cellular and humoral immunity and nonspecific resistance was observed. Conclusion. Association of combined therapy with immunocorrecting therapy promoting improving anti-infective resistance of the body seems to be pathogenetically reasonable in AtD complicated by a secondary infection.